High Ki-67 expression is associated with increased risk of distant recurrence in Oncotype Dx low risk breast cancer.

IF 2.9 3区医学 Q2 ONCOLOGY

Clinical breast cancer Pub Date : 2025-04-07 DOI:10.1016/j.clbc.2025.04.001

Soumaya Labidi, Nasser Mulla, Islam E Elkholi, Mariana Pilon Capella, April A N Rose, Lawrence Panasci, Cristiano Ferrario, Mark Basik, Parvaneh Fallah

{"title":"High Ki-67 expression is associated with increased risk of distant recurrence in Oncotype Dx low risk breast cancer.","authors":"Soumaya Labidi, Nasser Mulla, Islam E Elkholi, Mariana Pilon Capella, April A N Rose, Lawrence Panasci, Cristiano Ferrario, Mark Basik, Parvaneh Fallah","doi":"10.1016/j.clbc.2025.04.001","DOIUrl":null,"url":null,"abstract":"Purpose: To assess whether high Ki-67 protein expression level could independently predict the distant recurrence in early-stage breast cancer with low Oncotype Dx scores (≤ 25).Methods: This single-center retrospective cohort study included 278 patients with hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-), T1-2N0M0, low Oncotype Dx recurrence score (RS) (≤ 25) breast cancer. We identified 2 groups: \"high Ki-67″ ≥ 15% (n = 130, 47%) and \"low Ki-67″ < 15% (n = 148, 53%). Clinical characteristics, treatment and survival were abstracted from chart review. Fisher's exact test was used to assess differences between Ki-67 groups. Cox-regression models were used to assess differences in survival.Results: After a median follow up of 7 years, 13 (4.7%) patients experienced distant metastasis. Recurrence rate was significantly higher in the \"high Ki-67″ group 9.2% (12/130) versus the \"low Ki-67″ group 0.7% (1/148) (P = .001). Distant metastasis-free survival (dMFS) was significantly shorter in the \"high Ki-67″ group (HR 12.90, 95% CI, 12.53-13.27, P = .008). Tumor size ≥ 2 cm was associated with shorter dMFS (HR, 12.90; 95% CI, 12.53-13.27; P < .001). In a multivariable analysis, tumor size ≥ 2 cm and \"High Ki-67″ were independent prognosis factors for dMFS.Conclusion: Ki-67 expression level may help to identify a subset of low risk Oncotype Dx patients who could benefit from adjuvant chemotherapy.","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clbc.2025.04.001","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To assess whether high Ki-67 protein expression level could independently predict the distant recurrence in early-stage breast cancer with low Oncotype Dx scores (≤ 25).

Methods: This single-center retrospective cohort study included 278 patients with hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-), T1-2N0M0, low Oncotype Dx recurrence score (RS) (≤ 25) breast cancer. We identified 2 groups: "high Ki-67″ ≥ 15% (n = 130, 47%) and "low Ki-67″ < 15% (n = 148, 53%). Clinical characteristics, treatment and survival were abstracted from chart review. Fisher's exact test was used to assess differences between Ki-67 groups. Cox-regression models were used to assess differences in survival.

Results: After a median follow up of 7 years, 13 (4.7%) patients experienced distant metastasis. Recurrence rate was significantly higher in the "high Ki-67″ group 9.2% (12/130) versus the "low Ki-67″ group 0.7% (1/148) (P = .001). Distant metastasis-free survival (dMFS) was significantly shorter in the "high Ki-67″ group (HR 12.90, 95% CI, 12.53-13.27, P = .008). Tumor size ≥ 2 cm was associated with shorter dMFS (HR, 12.90; 95% CI, 12.53-13.27; P < .001). In a multivariable analysis, tumor size ≥ 2 cm and "High Ki-67″ were independent prognosis factors for dMFS.

Conclusion: Ki-67 expression level may help to identify a subset of low risk Oncotype Dx patients who could benefit from adjuvant chemotherapy.

查看原文本刊更多论文

在Oncotype Dx低危乳腺癌中，Ki-67高表达与远处复发风险增加相关。

目的：探讨Ki-67蛋白高表达水平是否能独立预测低Oncotype Dx评分（≤25）的早期乳腺癌远处复发。方法：单中心回顾性队列研究纳入278例激素受体阳性（HR+）人表皮生长因子受体2阴性（HER2-）、T1-2N0M0、低Oncotype Dx复发评分（RS）（≤25）的乳腺癌患者。我们确定了2组：“高Ki-67″≥15% （n = 130, 47%）”和“低Ki-67″< 15% （n = 148, 53%）”。临床特征，治疗和生存从图表回顾中摘录。使用Fisher精确检验来评估Ki-67组之间的差异。cox回归模型用于评估生存差异。结果：中位随访7年后，13例（4.7%）患者发生远处转移。复发率“高Ki-67″组”为9.2%(12/130)，“低Ki-67″组”为0.7%(1/148)，差异有统计学意义（P = .001）。“高Ki-67″”组远端无转移生存期（dMFS）显著缩短（HR 12.90, 95% CI, 12.53-13.27, P = 0.008）。肿瘤大小≥2 cm与较短的dMFS相关(HR, 12.90；95% ci, 12.53-13.27；P < 0.001)。在多变量分析中，肿瘤大小≥2 cm和“高Ki-67″”是dMFS的独立预后因素。结论：Ki-67表达水平可能有助于识别低风险的Oncotype Dx患者，这些患者可能从辅助化疗中获益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical breast cancer 医学-肿瘤学

CiteScore

5.40

自引率

3.20%

发文量

174

审稿时长

48 days

期刊介绍： Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.